HRP20240033T1 - Formulacija koja sadrži inhibitor mek - Google Patents
Formulacija koja sadrži inhibitor mek Download PDFInfo
- Publication number
- HRP20240033T1 HRP20240033T1 HRP20240033TT HRP20240033T HRP20240033T1 HR P20240033 T1 HRP20240033 T1 HR P20240033T1 HR P20240033T T HRP20240033T T HR P20240033TT HR P20240033 T HRP20240033 T HR P20240033T HR P20240033 T1 HRP20240033 T1 HR P20240033T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- preparation
- weight
- cancer
- hydroxyethyloxy
- Prior art date
Links
- 229940124647 MEK inhibitor Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 12
- 238000002360 preparation method Methods 0.000 claims 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000002062 proliferating effect Effects 0.000 claims 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 4
- 229960001021 lactose monohydrate Drugs 0.000 claims 4
- 235000019359 magnesium stearate Nutrition 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- 239000000377 silicon dioxide Substances 0.000 claims 4
- WWWTWPXKLJTKPM-UHFFFAOYSA-N 2-aminooxyethanol Chemical compound NOCCO WWWTWPXKLJTKPM-UHFFFAOYSA-N 0.000 claims 3
- YBTSZTNYTYAQKE-UHFFFAOYSA-N 6-(4-bromo-2-fluoroanilino)-7-fluoro-3-methylbenzimidazole-5-carboxylic acid Chemical compound OC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F YBTSZTNYTYAQKE-UHFFFAOYSA-N 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000008119 colloidal silica Substances 0.000 claims 3
- LNWFOZRVZUTGTO-UHFFFAOYSA-N CN1C(C=C(C(O)=O)C(NC(C=CC(Br)=C2)=C2F)=C2F)=C2N=C1.NOCCO Chemical compound CN1C(C=C(C(O)=O)C(NC(C=CC(Br)=C2)=C2F)=C2F)=C2N=C1.NOCCO LNWFOZRVZUTGTO-UHFFFAOYSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000002628 peritoneum cancer Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/08—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by cooling of the solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Metallurgy (AREA)
- Materials Engineering (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (13)
1. Farmaceutski pripravak, naznačen time što sadrži:
– 5-10% kristaliziranog (2-hidroksietiloksi)amida 6-(4-brom-2-fluorfenilamino)-7-fluor-3-metil-3H-benzimidazol-5-karboksilne kiseline,
– 50-60%, po mogućnosti 55-56%, monohidrata laktoze, te
– 20-40%, po mogućnosti 30-36%, mikrokristalne celuloze, prema težini pripravka.
2. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što dodatno sadrži:
– 1,5-2,5% umreženog karboksimetilceluloza-natrija,
– 0,5-0,9% magnezijevog stearata, te
– 0,1-1% koloidnog silicijevog dioksida/koloidnog bezvodnog silicijevog dioksida, prema težini pripravka.
3. Farmaceutski pripravak u skladu s patentnim zahtjevom 2, naznačen time što sadrži:
– 5-10% kristaliziranog (2-hidroksietiloksi)amida 6-(4-brom-2-fluorfenilamino)-7-fluor-3-metil-3H-benzimidazol-5-karboksilne kiseline,
– 50-60% monohidrata laktoze,
– 20-40% mikrokristalne celuloze,
– 2% umreženog karboksimetilceluloza-natrija,
– 0,75% magnezijevog stearata, te
– 0,25% koloidnog silicijevog dioksida/koloidnog bezvodnog silicijevog dioksida, prema težini pripravka.
4. Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time što sadrži:
– 5-10% kristaliziranog (2-hidroksietiloksi)amida 6-(4-brom-2-fluorfenilamino)-7-fluor-3-metil-3H-benzimidazol-5-karboksilne kiseline, prema težini pripravka,
– 55-56% monohidrata laktoze, prema težini pripravka,
– 30-36% mikrokristalne celuloze, prema težini pripravka,
– 2% umreženog karboksimetilceluloza-natrija, prema težini pripravka,
– 0,75% magnezijevog stearata, prema težini pripravka, te
– 0,25% koloidnog silicijevog dioksida/koloidnog bezvodnog silicijevog dioksida, prema težini pripravka.
5. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što sadrži 45 mg kristaliziranog (2-hidroksietiloksi)amida 6-(4-brom-2-fluorfenilamino)-7-fluor-3-metil-3H-benzimidazol-5-karboksilne kiseline.
6. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je farmaceutski pripravak u obliku pogodnom za oralnu primjenu u obliku jedinice doziranja.
7. Farmaceutski pripravak u skladu s patentnim zahtjevom 6, naznačen time što je farmaceutski pripravak u obliku tablete.
8. Farmaceutski pripravak u skladu s patentnim zahtjevom 7, naznačen time što je tableta obložena tableta.
9. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što je namijenjen upotrebi u liječenju proliferativne bolesti kod subjekta, gdje je proliferativna bolest po mogućnosti rak, po mogućnosti rak kojeg se bira između čvrstog tumora ili primarnog limfoma CNS.
10. Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što je proliferativna bolest rak kojeg se bira između melanoma, raka gušterače, raka jajnika, raka jajovoda, raka peritoneuma, raka žučovoda, raka debelog crijeva ili raka rektuma.
11. Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 10, naznačen time što je proliferativna bolest melanom.
12. Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 10, naznačen time što je proliferativna bolest rak debelog crijeva.
13. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time što sadrži:
– 6,25% kristaliziranog (2-hidroksietiloksi)amida 6-(4-brom-2-fluorfenilamino)-7-fluor-3-metil-3H-benzimidazol-5-karboksilne kiseline,
– 55,63% monohidrata laktoze,
– 35,13% mikrokristalne celuloze,
– 2,00% umreženog karboksimetilceluloza-natrija,
– 0,75% magnezijevog stearata, te
– 0,25% of koloidni silicijev dioksid/koloidni bezvodni silicijev dioksid, prema težini pripravka;
i gdje farmaceutski pripravak može sadržavati oblogu od filma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261716169P | 2012-10-19 | 2012-10-19 | |
EP19211405.6A EP3702351B1 (en) | 2012-10-19 | 2013-10-18 | Formulation comprising a mek inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20240033T1 true HRP20240033T1 (hr) | 2024-03-29 |
Family
ID=50488781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20240033TT HRP20240033T1 (hr) | 2012-10-19 | 2013-10-18 | Formulacija koja sadrži inhibitor mek |
Country Status (23)
Country | Link |
---|---|
US (7) | US9238627B2 (hr) |
EP (3) | EP4306171A3 (hr) |
JP (3) | JP6385939B2 (hr) |
CN (3) | CN104870427B (hr) |
AR (1) | AR099630A1 (hr) |
BR (1) | BR112015008623B1 (hr) |
CA (2) | CA2888474C (hr) |
CY (1) | CY1122670T1 (hr) |
DK (2) | DK3702351T3 (hr) |
ES (1) | ES2772498T3 (hr) |
FI (1) | FI3702351T3 (hr) |
HK (1) | HK1214254A1 (hr) |
HR (1) | HRP20240033T1 (hr) |
HU (1) | HUE047708T2 (hr) |
JO (1) | JOP20130304B1 (hr) |
LT (1) | LT3702351T (hr) |
PL (2) | PL3702351T3 (hr) |
PT (2) | PT2909182T (hr) |
RS (1) | RS65117B1 (hr) |
RU (2) | RU2018127873A (hr) |
SI (2) | SI3702351T1 (hr) |
TW (1) | TWI650316B (hr) |
WO (1) | WO2014063024A1 (hr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3702351T (lt) * | 2012-10-19 | 2024-01-10 | Array Biopharma, Inc. | Kompozicijos, apimančios mek inhibitorių |
CN105566225A (zh) * | 2015-02-16 | 2016-05-11 | 苏州晶云药物科技有限公司 | 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法 |
PT3463345T (pt) | 2016-06-03 | 2023-01-06 | Array Biopharma Inc | Combinações farmacêuticas |
US20230192625A1 (en) * | 2017-11-14 | 2023-06-22 | Shenzhen Targetrx, Inc. | Substituted benzimidazole compound and composition comprising same |
TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
US11395823B2 (en) * | 2018-01-09 | 2022-07-26 | Duke University | Topical administration of MEK inhibiting agents for the treatment of skin disorders |
WO2020212832A1 (en) * | 2019-04-16 | 2020-10-22 | Alembic Pharmaceuticals Limited | Process of preparation of benzimidazole compounds |
WO2021116901A1 (en) * | 2019-12-09 | 2021-06-17 | Biocon Limited | Forms of binimetinib and process for preparation thereof |
WO2022074011A1 (en) | 2020-10-05 | 2022-04-14 | Pierre Fabre Medicament | Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma |
CN112679438A (zh) * | 2020-12-31 | 2021-04-20 | 武汉九州钰民医药科技有限公司 | 制备司美替尼的方法 |
WO2023084489A1 (en) | 2021-11-15 | 2023-05-19 | Pfizer Inc. | Methods of treating coronavirus disease 2019 |
WO2024003942A1 (en) * | 2022-07-01 | 2024-01-04 | Natco Pharma Limited | An improved process for the preparation of selumetinib sulfate |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020002370A (ko) * | 1999-01-13 | 2002-01-09 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 벤조헤테로사이클 및 mek 억제제로서의 그의 용도 |
AU6068600A (en) * | 1999-07-16 | 2001-02-05 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
CN101486682B (zh) * | 2002-03-13 | 2013-08-14 | 阵列生物制药公司 | 作为mek抑制剂的n3烷基化苯并咪唑衍生物 |
US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
DE602004023207D1 (de) * | 2003-07-24 | 2009-10-29 | Warner Lambert Co | Benzimidazol-derivate als mek-hemmer |
WO2007002092A1 (en) | 2005-06-23 | 2007-01-04 | Array Biopharma Inc. | SNAr PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS |
BRPI0611993B1 (pt) | 2005-06-23 | 2023-11-28 | Array Biopharma, Inc. | Compostos de benzimidazol e seu processo de preparação |
TWI405756B (zh) | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
EP1966155A1 (en) * | 2005-12-21 | 2008-09-10 | AstraZeneca AB | Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer |
MX2010001244A (es) * | 2007-07-30 | 2010-08-31 | Ardea Biosciences Inc | Derivados de n-(arilamino) sulfonamidas que incluyen polimorfos como inhibidores de mek asi como composiciones, metodos de uso y de preparacion de los mismos. |
US8022057B2 (en) | 2007-11-12 | 2011-09-20 | Takeda Pharmaceutical Company Limited | MAPK/ERK kinase inhibitors |
EP2421612A1 (en) | 2009-04-21 | 2012-02-29 | Novartis AG | Heterocyclic compounds as mek inhibitors |
LT3702351T (lt) | 2012-10-19 | 2024-01-10 | Array Biopharma, Inc. | Kompozicijos, apimančios mek inhibitorių |
-
2013
- 2013-10-18 LT LTEP19211405.6T patent/LT3702351T/lt unknown
- 2013-10-18 AR ARP130103796A patent/AR099630A1/es not_active Application Discontinuation
- 2013-10-18 CA CA2888474A patent/CA2888474C/en active Active
- 2013-10-18 PT PT138471065T patent/PT2909182T/pt unknown
- 2013-10-18 EP EP23211278.9A patent/EP4306171A3/en active Pending
- 2013-10-18 RS RS20240112A patent/RS65117B1/sr unknown
- 2013-10-18 BR BR112015008623-3A patent/BR112015008623B1/pt active IP Right Grant
- 2013-10-18 EP EP13847106.5A patent/EP2909182B1/en active Active
- 2013-10-18 US US14/057,498 patent/US9238627B2/en active Active
- 2013-10-18 EP EP19211405.6A patent/EP3702351B1/en active Active
- 2013-10-18 JP JP2015538050A patent/JP6385939B2/ja active Active
- 2013-10-18 TW TW102137813A patent/TWI650316B/zh active
- 2013-10-18 HU HUE13847106A patent/HUE047708T2/hu unknown
- 2013-10-18 SI SI201332074T patent/SI3702351T1/sl unknown
- 2013-10-18 CN CN201380063271.5A patent/CN104870427B/zh active Active
- 2013-10-18 PT PT192114056T patent/PT3702351T/pt unknown
- 2013-10-18 RU RU2018127873A patent/RU2018127873A/ru not_active Application Discontinuation
- 2013-10-18 WO PCT/US2013/065633 patent/WO2014063024A1/en active Application Filing
- 2013-10-18 FI FIEP19211405.6T patent/FI3702351T3/fi active
- 2013-10-18 DK DK19211405.6T patent/DK3702351T3/da active
- 2013-10-18 PL PL19211405.6T patent/PL3702351T3/pl unknown
- 2013-10-18 HR HRP20240033TT patent/HRP20240033T1/hr unknown
- 2013-10-18 CN CN201811124073.6A patent/CN109336824B/zh active Active
- 2013-10-18 RU RU2015118572A patent/RU2669391C2/ru active
- 2013-10-18 DK DK13847106.5T patent/DK2909182T3/da active
- 2013-10-18 CA CA3079071A patent/CA3079071C/en active Active
- 2013-10-18 PL PL13847106T patent/PL2909182T3/pl unknown
- 2013-10-18 CN CN201810684986.7A patent/CN109456272A/zh active Pending
- 2013-10-18 SI SI201331672T patent/SI2909182T1/sl unknown
- 2013-10-18 ES ES13847106T patent/ES2772498T3/es active Active
- 2013-10-20 JO JOP/2013/0304A patent/JOP20130304B1/ar active
-
2015
- 2015-12-18 US US14/974,655 patent/US9562016B2/en active Active
- 2015-12-18 US US14/974,588 patent/US9382212B1/en active Active
-
2016
- 2016-02-25 US US15/053,441 patent/US9598376B2/en active Active
- 2016-02-25 HK HK16102126.5A patent/HK1214254A1/zh unknown
-
2017
- 2017-02-28 US US15/445,393 patent/US9980944B2/en active Active
- 2017-12-14 US US15/842,715 patent/US10398683B2/en active Active
-
2018
- 2018-06-07 JP JP2018109486A patent/JP6737838B2/ja active Active
-
2019
- 2019-07-16 US US16/512,823 patent/US10729678B2/en active Active
- 2019-08-19 JP JP2019149828A patent/JP2019194272A/ja active Pending
-
2020
- 2020-02-18 CY CY20201100148T patent/CY1122670T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20240033T1 (hr) | Formulacija koja sadrži inhibitor mek | |
HRP20191587T1 (hr) | Formulacije s trenutnim oslobađanjem za oralnu primjenu supstituiranih kinazolinona | |
HRP20200561T1 (hr) | Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti | |
HRP20171793T1 (hr) | Farmaceutske formulacije koje sadrže kristalne oblike (r)-7-kloro-n-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamid hidroklorid monohidrata | |
RS54329B1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING RIFAXIMINE, PROCEDURES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS | |
HRP20211140T1 (hr) | Pripravci protiv raka | |
NZ729172A (en) | Combination formulation of two antiviral compounds | |
Tran et al. | Preparation and characterization of pH-independent sustained release tablet containing solid dispersion granules of a poorly water-soluble drug | |
HRP20191000T1 (hr) | Spojevi za vezanje nhe3 i metode inhibiranja transporta fosfata | |
JP2017525712A5 (hr) | ||
JP2015038155A5 (hr) | ||
HRP20221018T1 (hr) | Liječenje katapleksije | |
PH12015501015B1 (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
JP2020500875A5 (hr) | ||
JP2014532638A5 (hr) | ||
JP2015038135A5 (hr) | ||
JPWO2013054872A1 (ja) | 7−[4−(4−ベンゾ[b]チオフェン−4−イル−ピペラジン−1−イル)ブトキシ]−1H−キノリン−2−オン又はその塩を含む錠剤 | |
JP2016516698A5 (hr) | ||
JP2014218522A5 (hr) | ||
JP2016532655A5 (hr) | ||
HRP20221269T1 (hr) | Pripravci za liječenje mijelofibroze | |
KR20130086128A (ko) | 복용 용이성 고형 제제 | |
HRP20220929T3 (hr) | Sastav za inhalaciju koji sadrži aklidinij za liječenje astme | |
WO2016210003A3 (en) | 17-hydroxyprogesterone ester-containing oral compositions and related methods | |
IL255782A (en) | Pharmacotherapeutic agents of levatiracetam with prolonged release |